Forward Looking Statements Unlocking 4 Billion Years of Microbial Evolution to Create Curative Genetic Medicines Nasdaq: MGX May 2025 This presentation includes forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation are forward looking statements, including statements regarding our cash runway, strategy and plans, industry environment, ...

Core Insights - Metagenomi, Inc. has made significant advancements in gene editing technologies, particularly for treating neurological disorders through extrahepatic in vivo gene editing [1][2] - The company presented three abstracts at the ASGCT 28 Annual Meeting, showcasing its proprietary gene editing toolbox, including compact nucleases and CRISPR-associated transposases (CAST) [1][2] Gene Editing Technologies - The metagenomics discovery platform utilizes natural microbial evolution and AI-guided protein optimization to identify and enhance novel gene editing systems [2] - Compact Type II and Type V nucleases have been developed for efficient in vivo editing, with a focus on delivering large therapeutic genes [2][9] - The CAST system has shown promise in addressing challenges related to targeted and precise large gene integration [2] Presentation Highlights - A compact type II CRISPR system (MG21-1) demonstrated up to 69% target protein reduction in the CNS with localized AAV9 delivery [6] - An ultra-compact type V nuclease (MG119-28) achieved over 50% restoration of dystrophin protein levels in DMD model myocytes and 64% knockdown of target protein in the motor cortex [6] - The type V-K CAST system has improved integration efficiency by over 50 times compared to natural systems, indicating its potential for therapeutic applications [9] Company Overview - Metagenomi leverages AI and machine learning to develop next-generation genome editing therapeutics, analyzing over 7.4 billion proteins to target various genetic mutations [7] - The company has a lead program in Hemophilia A, aiming to provide lifelong protection from bleeding events and joint damage [7]

Metagenomi (MGX) came out with a quarterly loss of $0.68 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to loss of $1.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -9.68%. A quarter ago, it was expected that this genetic medicines company would post a loss of $0.62 per share when it actually produced a loss of $0.63, delivering a surprise of -1.61%.Over the last four quarters, the company ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41949 Metagenomi, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-3909017 (State or other jurisdiction of ...

Financial Performance - As of March 31, 2025, Metagenomi reported cash, cash equivalents, and available-for-sale marketable securities of $226.0 million, expected to support operations into 2027[1][9] - Research and development (R&D) expenses for Q1 2025 were $25.1 million, a decrease from $31.4 million in the same period of 2024, representing a reduction of approximately 20.5%[9][10] - General and administrative (G&A) expenses for Q1 2025 were $6.8 million, down from $8.8 million in Q1 2024, indicating a decrease of approximately 22.7%[10] - Collaboration revenue for Q1 2025 was reported at $4.1 million, a significant decrease from $11.2 million in Q1 2024[20] - The net loss for Q1 2025 was $25.0 million, slightly improved from a net loss of $25.1 million in Q1 2024[20] Research and Development - The nonhuman primate (NHP) study for the Hemophilia A program showed FVIII activity levels of 80%, 10%, and 32% in three animals at the 19-month mark, correlating with gene integration frequencies of 5.3%, 0.89%, and 2.5% respectively[3] - The mean FVIII activity during months 12-19 post lipid nanoparticle dosing was 75%, with individual results of 8% and 29% for two of the animals[3] - The company plans to leverage findings from the NHP study to inform the strategy for the MGX-001 program moving forward[2] Technological Advancements - Metagenomi's AI-driven metagenomics platform has analyzed over 7.4 billion proteins, enhancing its gene editing capabilities[13] - The company anticipates additional advancements in its compact CRISPR-associated transposase (CAST) systems for clinical applications in 2025[7]

- Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximately 19 months with an encouraging safety profile - Well capitalized with $226.0 million in cash, cash equivalents and available-for-sale marketable securities as of March 31, 2025 with runway anticipated to support operations into 2027 EMERYVILLE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company ...

EMERYVILLE, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today announced that the Company will present at two upcoming scientific meetings: an oral presentation at TIDES USA 2025, taking place May 19-22, 2025, at the Manchester Grand Hyatt San Diego, and three poster presentations at the American Society of Gene & Cell Therapy (ASGCT) 2025 A ...

Exhibit 99.1 Metagenomi Reports Business Updates and Full Year 2024 Financial Results Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhuman primate (NHP) study for more than 16 months Leveraged hemophilia A albumin platform to achieve in vivo proof-of-concept in multiple secreted protein deficiencies to support wholly-owned follow-on program Progressed four Wave 1 Ionis targets to lead optimization with plans to ...

Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhuman primate (NHP) study for more than 16 months Leveraged hemophilia A albumin platform to achieve in vivo proof-of-concept in multiple secreted protein deficiencies to support wholly-owned follow-on program Progressed four Wave 1 Ionis targets to lead optimization with plans to declare one to two development candidates (DCs) in 2025 Well capitalized with $248.3 ...

Financial Performance - Collaboration revenue increased to $52.3 million for the year ended December 31, 2024, compared to $44.8 million in 2023, reflecting a growth of approximately 33.3%[558] - Collaboration revenue increased by $7.5 million, from $44.8 million in 2023 to $52.3 million in 2024, primarily driven by an $8.5 million increase from the Ionis Agreement[572] - The net loss for 2024 was $78.1 million, compared to a net loss of $68.3 million in 2023, reflecting an increase of $9.8 million[581] - Total operating expenses rose to $141.2 million in 2024, up $17.9 million from $123.2 million in 2023, with research and development expenses accounting for $109.2 million, an increase of $14.8 million[574] - Total other income, net, decreased by $12.9 million, from $18.3 million in 2023 to $5.3 million in 2024, primarily due to a loss of $9.2 million on long-term investments[576] - The provision for income taxes changed from an expense of $8.0 million in 2023 to a benefit of $5.5 million in 2024, reflecting a strategic tax credit carryback[577] - The company has an accumulated deficit of $223.0 million as of December 31, 2024, indicating ongoing financial challenges[581] Cash Flow and Liquidity - Cash used in operating activities was $109.1 million for 2024, consisting mainly of the net loss and changes in operating assets and liabilities[586] - As of December 31, 2024, the company had $248.3 million in cash, cash equivalents, and available-for-sale marketable securities, sufficient to fund projected operating expenses for at least the next 12 months[582] - Net cash used in operating activities for the year ended December 31, 2023 was $91.4 million, primarily due to a net loss of $68.3 million and a net reduction of $26.4 million in net operating assets and liabilities[587] - Net cash provided by investing activities for the year ended December 31, 2023 was $45.7 million, consisting of $55.5 million in net maturities of available-for-sale marketable securities, offset by $9.8 million of purchases of property and equipment[589] - Net cash provided by financing activities for the year ended December 31, 2024 was $84.0 million, attributed to net proceeds from the issuance of common stock in the IPO[590] - Net cash used in investing activities for the year ended December 31, 2024 was $88.2 million, primarily due to net purchases of available-for-sale securities of $84.7 million[588] - Net cash provided by financing activities for the year ended December 31, 2023 was $1.0 million, consisting of $4.3 million of net cash proceeds from the issuance of Series B-1 preferred redeemable convertible preferred stock[591] Research and Development - The investigational therapy for hemophilia A demonstrated durable FVIII activity levels in non-human primates over a 16.5-month period, with no significant safety findings reported[547] - The company plans to conduct pre-IND and ex-U.S. regulatory meetings in 2025 and aims to complete IND and clinical trial application filings for MGX-001 in 2026[547] - Research and development expenses are expected to increase substantially as the company continues to invest in its platform and advance clinical trials[562] General and Administrative Expenses - General and administrative expenses are anticipated to rise due to increased headcount and costs associated with being a public company[564] - General and administrative expenses increased to $32.0 million in 2024, up $3.2 million from $28.8 million in 2023, primarily due to increased stock-based compensation[575] Collaborations and Partnerships - The company has entered into collaborations with Ionis Pharmaceuticals and Affini-T Therapeutics to develop gene editing therapies for cardiometabolic diseases and cancer, respectively[548][555] - The company has not generated any revenue from product sales and does not expect to do so in the foreseeable future, relying instead on collaboration agreements for revenue[556] Corporate Actions - The company completed its initial public offering (IPO) on February 13, 2024, issuing 6,250,000 shares at $15.00 per share, resulting in net proceeds of approximately $80.7 million after costs[552] - The Reorganization and reverse stock split were completed on January 24, 2024, and January 26, 2024, respectively, with a 1-for-1.74692 ratio for the stock split[549][551] Tax and Deferred Assets - As of December 31, 2024, the company had net operating loss carryforwards of $45.6 million for federal and $118.3 million for state income tax purposes, available to reduce future taxable income[567] - The company assesses the need for a valuation allowance against deferred tax assets based on various factors, including projected future taxable income and historical earnings experience[609] - The company recognizes tax benefits related to uncertain tax positions when it is more likely than not that a tax position will be sustained during an audit[610]